ArticleCureus2026
Locally Advanced Basal Cell Carcinoma With Orbital Invasion: Treatment With Neoadjuvant Hedgehog Pathway Inhibition and Palliative Enucleation.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 63‑year‑old man with a history of heavy tobacco use presented to the hospital with a 2 × 3 cm necrotic lesion of the left temporal region associated with pain and progressive vision loss in the left eye. Biopsy of the left lateral orbital wall demonstrated locally invasive basal cell carcinoma (BCC). The patient was referred to a National Cancer Institute-designated comprehensive cancer center for further management. He was initiated on neoadjuvant hedgehog pathway inhibition with vismodegib and had an excellent oncologic response. Despite this, visual acuity in the left eye continued to decline and was accompanied by worsening proptosis and pain, which was refractory to multimodal analgesia. The patient was referred to ocular oncology, and vismodegib was discontinued after six months of treatment in anticipation of surgery. The patient underwent left eye enucleation and reported complete resolution of pain. He showed no evidence of residual disease four months after completion of vismodegib therapy. This report highlights a rare case of locally advanced periocular BCC with orbital invasion managed with neoadjuvant hedgehog pathway inhibition and palliative enucleation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.